Structure Therapeutics said it plans to move its once-daily oral GLP-1 receptor agonist aleniglipron into Phase III clinical development after reporting positive topline results from its Phase II ACCESS program in adults with obesity or overweight and weight-related comorbidities. The company, a clinical-stage biopharmaceutical firm focused on oral small molecule therapies for metabolic disease, expects […]